Clinical trial

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02172352

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Ba 679 BR low dose Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Ba 679 BR middle dose Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Ba 679 BR high dose Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo inhalation powder Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date1998-07-01

PhasePHASE2

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

Ba 679 BR low doseDRUG

Ba 679 BR middle doseDRUG

Ba 679 BR high doseDRUG

Placebo inhalation powderDRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02172352 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.